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Background: Men with coronary artery disease (CAD) have been shown to have enhanced 
arterial stiffness. Arterial function may change over time according to treatment, but the 
prognostic value of these changes has not been investigated.
Objectives: The aim of the present study was to assess whether an improvement in large artery 
rigidity in response to treatment, could predict a more favorable prognosis in a population of 
men with CAD.
Methods: A total of 161 men with CAD (mean age 56.8 ± 10.9 years) being treated with 
conventional therapy underwent brachial-ankle pulse wave velocity (PWVba) measurements at 
baseline and after six months. Follow-up period was 3.5 years. End-points were major adverse 
cardiac events (MACE): acute myocardial infarction, unstable angina, coronary intervention, 
or cardiac death.
Results: During the three-year follow-up period (since initial six-month follow-up), 30 patients 
experienced MACE. After six-month follow-up, PWVba had not improved (∆PWVba $ 0%, 
relative to baseline) in 85 (52.8%) of 161 men (Group 1), whereas it had improved 
(∆PWVba , 0%) in the remaining 76 men (47.2%) (Group 2). During follow-up, we noticed 
24 cardiovascular events in Group 1 and six events in Group 2 (P , 0.001). Cox proportional 
hazards analyses demonstrated that independent of conventional risk factor changes, absence 
of PWVba decrease was a predictor of MACE (RR 3.99; 95% CI:1.81–8.78; P = 0.004). The 
sensitivity of ∆PWVba was 80% and its specificity was 54%.
Conclusions: This study demonstrates that an improvement in arterial stiffness may be obtained 
after six months of conventional therapy and clearly identifies patients who have a more favor-
able prognosis.
Keywords: arterial stiffness, coronary artery disease, prognosis
Introduction
Elevated arterial stiffness has been associated with progression of cardiovascular 
morbidity and mortality due to arterial hypertension, end-stage renal failure, 
diabetes mellitus, and other conditions.1–3 Data exist to show that decreased arterial 
elasticity is a predictor of future development of cardiovascular complications 
in patients with coronary artery disease (CAD).4,5 In order to consider increased 
arterial stiffness as something necessitating therapeutic focus, crucial data has been 
acquired showing that decreasing arterial rigidity leads directly to a decreased risk 
of major adverse cardiac events (MACE). Obtaining such confirmation was the 
purpose of this work.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Methods
Patients
After giving informed consent, ambulatory patients aged 
35–75 years, with proven clinically stable coronary artery 
disease, were considered for the study. Eligible participants 
were recruited by the outpatient department of the   Russian 
Cardiology Research Center in Moscow if they met at 
least one of the following inclusion criteria: 1) history of 
myocardial infarction; 2) angiographic evidence of at least 
50% stenosis in at least one coronary artery; 3) evidence of 
exercise-induced ischemia on treadmill electrocardiogram or 
stress nuclear perfusion imaging; or 4) history of coronary 
revascularization.
The study began in September 2004 and recruitment 
was completed in September 2005. The mean ± SD for 
follow-up was 586 ± 461 days. Of the 224 consecutive 
patients initially screened, 161 remained on the study for 
our 6-month follow-up examination. All 161 patients were 
white males, with a 12% prevalence of diabetes mellitus 
(Table 1). The mean ± SD age of the cohort at inclusion 
was 56.8 ± 10.9 years. Major exclusion criteria included: 
acute myocardial infarction (MI) or stroke within the past 
three months; percutaneous coronary intervention (PCI), 
coronary-artery bypass grafting (CABG), implantation, or 
planned implantation of a cardioverter defibrillator or biven-
tricular pacemaker within the past three months; clinically 
significant, uncorrected primary valvular heart; hypertrophic 
cardiomyopathy; systemic disease; acute or chronic liver dis-
ease; plasma creatinine level .2.5 mg/dL; current presence 
of clinical signs of heart failure, and ejection fraction below 
40% as assessed locally by echocardiography or another 
method if echocardiography was technically impossible; 
diabetes mellitus (DM) requiring medication; any other 
condition that would substantially reduce life expectancy or 
limit compliance with the protocol.
All patients received conventional therapy. Characteristics 
of the studied population are reported in Table 1.
Data collection
Information compiled from the questionnaire filled out at 
inclusion included: personal and family histories; smoking 
habits; and prior history of cardiovascular disease, including 
cardiac insufficiency, peripheral vascular disease, and 
cerebrovascular disease. Twice—at baseline and after six 
months—blood pressure (BP), fasting blood glucose (FBG), 
serum total cholesterol (TC), triglycerides (TG), body mass 
index (BMI), arterial stiffness, and other risk factors were 
assessed. BP was measured in the right arm after five minutes 
of recumbence using a mercury sphygmomanometer and cuff 
of appropriate size. Phases I and V of the Korotkoff sounds 
were taken as the systolic BP (SBP) and diastolic BP (DBP) 
values respectively. The mean BP (MBP) was calculated as 
follows: MBP = DBP + [(SBP – DBP)/3]. Three measure-
ments were made at two-minute intervals; the last two mea-
surements were averaged and considered to be representative. 
The patient’s heart rate was determined from the three-lead 
orthogonal ECG. Arterial stiffness was assessed using the 
brachial-ankle pulse wave velocity (PWVba) with a VaSera 
VS-1000 device (Fukuda Denshi, Tokyo, Japan).6,7 Measure-
ments were made according to the recommendations for user 
procedures.8 The PWVba was measured at inclusion and 
again after six months. The change in PWVba (∆PWVba), 
measured in meters per second (m/s) and used as a prognostic 
variable, was quantified as follows: ∆PWVba = (PWVba after 
six months) – (PWVba at inclusion).
Follow-up
The patients were followed every six months. Upon follow-up, 
patients were asked to fill out a questionnaire regarding hos-
pitalizations and outpatient clinic visits in the preceding six 
months. ACE of interest for this study were acute myocardial 
infarction, unstable angina, coronary intervention, or cardiac 
death. When a possible event was recorded by the participant, 
hospital discharge letters, results of laboratories, and other 
relevant examinations were collected.
Analyses
The primary analysis concerned the survival curves and Cox 
proportional hazards model. Survival was estimated by the 
Kaplan–Meier product-limit method and compared using 
Table 1 characteristics of studied population (n = 161)
Age, years (mean ± sD) 56.8 ± 10.9
Patients with a previous Mi (%) 101 (62.7%)
Patients with angina pectoris (%) 113 (70.2%)
Patients with hypertension (%) 113 (70.2%)
current smokers (%) 48 (29.8%)
Patients with DM (%) 20 (12.4%)
Medication
Acetylsalicylic acid and/or clopidogrel (%) 141 (87.6%)
nitrates (%) 27 (16.8%)
β-blockers (%) 132 (82.0%)
calcium channel blockers (%) 30 (18.6%)
Acei or ARB (%) 93 (57.8%)
statins (%) 133 (82.6%)
Abbreviations: sD, standard deviation; Mi, myocardial infarction; DM, diabetes 
mellitus;  Acei,  angiotensin-converting  enzyme  inhibitor;  ARB,  angiotensin  ii 
receptor blockers.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the Mantel (log-rank) test. Factors prognostic of survival 
were identified with use of the Cox proportional hazards 
regression model. The assumption of proportional hazards 
over time was verified before the analyses and was met by all 
covariates. The assumption concerning linearity of continu-
ous covariates was also verified before analysis. Multivariate 
Cox modeling was the primary statistical analysis used to 
determine the independent relationship of PWV changes 
and other baseline characteristics with survival. Variables 
were considered to be prognostic when they were found to 
be statistically significant in the Cox proportional hazards 
regression model (P , 0.05, adjusted for all variables retained 
in the final model). Adjusted hazard rate ratios (RR) were 
calculated as the antilogarithm of the ß coefficient of the Cox 
proportional hazards regression of the outcome events, with 
different variables entered in the models. The 95% confidence 
intervals (CI) for the adjusted RR estimates were obtained 
using the following formula: antilogarithm (ß ± 1.96 SE), 
where SE is the standard error of ß.
To assess ∆PWV as a prognostic variable test with the 
use of receiver operating characteristic (ROC) curves, we 
calculated sensitivities, specificities, positive predictive 
values, and negative predictive values to predict mortality 
at different cutoff values. Optimal PWV cutoff values were 
defined as the maximization of the sum of sensitivity and 
specificity.
Data are expressed as mean ± SD for normally distributed 
variables or median (lowest quartile; highest quartile) for not 
normally distributed variables. ANOVA was used for com-
parison of normally distributed variables and in the alternative 
situation, the non parametric equivalent Kruskal–Willis test 
was used. Differences in frequency were tested by χ2 analy-
sis. All tests were two-sided, and analyses were performed 
using SPSS (v. 14.0;SPSS, Chicago, IL) and STATISTICA 
(v. 6.0;Statsoft, Tulsa. OK) software. A value of P , 0.05 
was considered significant.
Results
In the studied cohort, from six months until the end of the 
study, we recorded 30 cardiovascular complications: six 
MI, 11 PCI and CABG, 10 hospitalizations due to unstable 
angina, and three cardiac deaths. Patients who experienced 
MACE in the first six months of observation were not 
included in our analyses. All investigating parameter changes, 
from inclusion until six months time, are reported in Table 2. 
For the first six months, only diastolic BP and MAP showed 
a small (non significant) decrease, while all other parameters 
remained unchanged.
The ∆PWV was correlated with changes in MAP 
(r = 0.36; P , 0.001), SBP (r = 0.32; P , 0.001), DBP 
(r = 0.32; P , 0.001), but not to ∆FGB, ∆TC, or ∆TG.
Patients were separated into two groups based on the 
direction of change in the stiffness of their arterial walls. 
The ROC curve showed that the cutoff value for ∆PWV 
was 0.05 m/s (ie, ≅ 0). Area under the curve was 0.62 ± 0.05 
(P = 0.032). In six months, PWVba decreased in 76 patients 
(Group 1) and in the other 85 patients, either an increase or 
no change was observed (Group 2). In patients who were 
observed to have improved mechanical characteristics of 
their large arteries in the first six months, there were six 
MACE, while the others had 24 MACE. In our analyses, an 
increased or unchanged PWVba was defined as “positive” 
and a decrease in PWVba was considered “negative”. 
Characteristics of patients in each group are provided in 
Table 3.
In patients with a demonstrated decrease in PWVba 
at six months (Group 1), it was shown that there was a 
higher baseline PWVba 14.19 ± 2.40 m/s, compared with 
13.15 ± 2.16 m/s (P = 0.004) in Group 2.
For 70 of 76 patients in Group 1, there were no MACE in 
the last three years of the study, while 24 out of 85 patients 
in Group 2 had complications. The sensitivity of ∆PWV was 
80% and its specificity was 54%.
Thus, with the aid of univariate Cox proportional hazard 
regression analysis, we studied the influence of given 
parameters, at the six-month follow-up, on the occurrence of 
MACE in the next three years. Absence of arterial stiffness 
decrease was a predictor of MACE. Increase, or absence of 
change in PWVba (positive ∆PWVba), increased the risk 
of MACE in the following three years by nearly four times 
(RR 3.77; 95% CI:1.83–7.77; t = 3.02, P = 0.003).
Table 2 changes in investigating parameters from inclusion until 
six months of follow-up in entire cohort 
Baseline 
(mean ± SD)
Six months 
(mean ± SD)
P-value
PWVba (m/s) 13.60 ± 2.44 13.75 ± 2.27 0.315
sBP (mmHg) 135.2 ± 19.2 135.9 ± 14.9 0.431
DBP (mmHg) 87.4 ± 11.5 86.6 ± 10.2 0.060
PP (mmHg) 48.9 ± 12.0 49.6 ± 11.8 0.152
MAP (mmHg) 103.0 ± 13.4 102.7 ± 12.1 0.088
FBg (mmol/L) 5.98 ± 1.36 5.75 ± 1.00 0.203
Tc (mmol/L) 5.07 ± 1.29 5.10 ± 1.14 0.428
Tg (mmol/L)  1.33 (0.97; 1.91)* 1.23 (0.94; 181)* 0.139
Note: *Tg values are the median (lowest quartile; highest quartile).
Abbreviations: sD, standard deviation; PWVba, brachial-ankle pulse wave velocity; 
sBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure;   
MAP, mean arterial pressure; FBg, fasting blood glucose; Tc, serum total cholesterol; 
Tg, triglycerides.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The role of factors such as smoking, BMI, previous 
MI, and DM were not found to be significant. Only 12% of 
patients were found to have DM and all of these were treated 
with dietary adjustments. Age at baseline was not correlated 
with prognosis in this cohort (RR 0.99; 95% CI:0.96–1.03, 
P = 0.787). Six-month change in SBP (RR 0.99; 95% 
CI:0.67–1.01; P = 0.270), DBP (RR 0.97; 95% CI:0.94–1.01; 
P = 0.159), PP (RR 0.99; 95% CI:0.97–1.02; P = 0.600), 
MAP (RR 0.98–1.01; 95% CI:0.95–1.01; P = 0.171), and 
blood chemistry were not significant. Also, the type of medi-
cation was not found to be predictive of outcome.
To assess the influence of changes in PWVba on 
occurrence of MACE when considering the contribution of 
other factors, three models of the Cox proportional hazards 
regression, with a different set of dependent variables, 
have been created (Table 4). ∆PWVba was not found to 
influence prognosis, when age at baseline, and changes 
in MAP at six-month follow-up here applied to the first 
model (Model 1). In Model 2, we included ∆PWVba, ∆TC, 
and ∆SBP at six months, as well as age and whether the 
patient was a smoker at the moment of inclusion. After 
applying adjustments for other studied factors (Model 3), 
PWVba was still found to have an influence on prognosis 
(Table 4).
Kaplan–Meier curves show the probabilities of event-free 
survival of patients with negative ∆PWV or positive ∆PWV 
(Figure 1).
Discussion
Carotid-femoral PWV method is considered to be the 
“gold standard” for measurement of arterial rigidity. This 
method has been used in the majority of epidemiological 
studies demonstrating the predictive value of aortic stiffness 
for cardiovascular events. In their studies preceding our 
investigation, Japanese researchers focused on the value 
of brachial-ankle pulse wave velocity (PWVba) testing 
and showed the aortic PWV as the primary independent 
correlate of PWVba.9 We employed the PWVba method 
after considering that it is simple to use, inexpensive, well 
reproduced, and its informative value has been demonstrated 
in multiple studies.5–7,10 Additionally, we used the PWVba 
method because it is more comfortable for the average patient, 
Table 3 characteristics of patients in groups with “negative” 
and  “positive”  PWVba  dynamics  for  the  first  six  months  of 
observation (n = 161)
  ΔPWVba , 0 
(n = 76)
ΔPWVba $ 0 
(n = 85)
P-value
Patients with history  
of MAce (%)
6 (7.9%) 24 (28.2%) 0.001
Age (mean years ± sD) 56.9 ± 10.8 56.8 ± 11.0 0.649
Patients with a  
previous Mi (%)
46 (60.5%) 55 (64.7%) 0.626
Patients with  
hypertension (%)
53 (69.7%) 60 (70.6%) 1.000
Patients with angina 
pectoris (%)
52 (68.4%) 61 (71.7%) 0.731
current smokers (%) 23 (30.3%) 25 (29.4%) 1.000
Patients with DM (%) 12 (15.8%) 8 (9.4%) 0.242
sBP (mmHg) 139.1 ± 19.4 133.0 ± 18.8 0.046
DBP (mmHg) 90.0 ± 11.5 85.8 ± 11.8 0.023
MAP (mmHg) 106.4 ± 13.4 101.5 ± 13.4 0.024
BMi (kg/m2) 27.6 ± 3.6 27.3 ± 4.0 0.538
FBg (mmol/L) 5.95 ±1.36 5.76 ± 0.92 0.320
Tc (mmol/L) 5.32 ± 1.39 4.88 ± 1.26 0.042
Tg (mmol/L) 1.26 (1.03; 1.77) 1.37 (0.90; 1.35) 0.836
Medication
Acetylsalicylic acid  
and/or clopidogrel (%)
67 (94.7%) 74 (97.4%) 0.430
nitrates (%) 11 (15.5%) 16 (21.1%) 0.404
β-blockers (%) 65 (91.6%) 67 (88.2%) 0.591
calcium channel  
blockers (%)
11 (15.5%) 19 (25.0%) 0.218
Acei or ARB (%) 45 (63.2%) 48 (63.2%) 1.000
statins (%) 60 (84.5%) 73 (96.1%) 0.023
Notes: Values are number of cases (%) or the mean ± standard deviation, except 
for Tg, which is expressed as the median (lowest quartile; highest quartile).
Abbreviations: PWVba, brachial-ankle pulse wave velocity; sD, standard deviation; 
MAce, major cardiovascular adverse event; Mi, myocardial infarction; DM, diabetes 
mellitus;  sBP,  systolic  blood  pressure;  DBP,  diastolic  blood  pressure;  MAP,  mean 
arterial  pressure;  BMi,  body  mass  index,  FBg,  fasting  blood  glucose; Tc,  serum 
total cholesterol; Tg, triglycerides; Acei, angiotensin-converting enzyme inhibitor;   
ARB, angiotensin ii receptor blockers.
Table 4 Multivariate cox proportional hazard regression analyses of MAce (n = 161)
RR 95% CI t-value P-value
Model 1 (P = 0.004)
∆PWVba (1 = positive/0 = negative) adjusted ∆MAP and age at baseline 4.40 2.03–9.52 3.17 0.002
Model 2 (P = 0.007)
∆PWVba (1 = positive/0 = negative) adjusted ∆sBP, ∆Tc, current smoking, and age at baseline 4.57 2.08–10.06 3.18 0.002
Model 3 (P = 0.005)
∆PWVba (1 = positive/0 = negative) adjusted ∆sBP, ∆DBP, ∆Tc, current smoking and age at  
baseline, previous Mi, DM, Acei/ARB use
3.99 1.81–8.78 2.90 0.004
Abbreviations: RR, rate ratio; CI, confidence intervals; PWVba, brachial-ankle pulse wave velocity; MAP, mean arterial pressure; SBP, systolic blood pressure; TC, total cholesterol; 
DBP, diastolic blood pressure; Mi, myocardial infarction; DM, diabetes mellitus; Acei, angiotensin-converting-enzyme inhibitor; ARB, angiotensin ii receptor blockers.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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since it allows him/her to remain fully dressed during the 
procedure.
Our own previous publications, as well as those by other 
investigators, have shown that increased arterial rigidity 
in patients with CAD is associated with increased risk of 
MACE.5,4,11 The expert consensus on arterial stiffness states 
that clinical trials need to be conducted in order to determine 
whether a reduction in arterial stiffness is a desirable 
therapeutic goal, in terms of hard clinical endpoints such as 
morbidity and mortality.12 In the current study, we aimed to 
answer the question of whether a decrease in arterial stiff-
ness leads to improved prognosis in male patients suffering 
from CAD.
Based on the data from the group as a whole, we did not 
note distinctions in the levels of PWVba, BP, TC, TG, and 
FBG throughout the term of the study. Regression analysis 
demonstrated that ∆PWVba was significantly correlated 
with ∆BP. The closest correlation we found was between 
∆PWVba and delta MAP (r = 0.36; P , 0.001). In many 
studies executed on hypertensive and normotensive patients, 
there is a parallel decrease in BP and PWV as a result of 
therapy.13,14 However, it is important to remember that in 
and of itself, BP is one of the most meaningful factors of 
cardiovascular risk and a decrease in BP results in improved 
prognosis.15 The next question is whether reduction of mor-
bidity and mortality in patients with cardiovascular pathol-
ogy is only due to the influence of therapy on BP, or if some 
medications possess their own additional influence on the 
patient’s prognosis. In the last few years, there have been a 
few published studies focusing on some medications which 
have a “BP-independent” positive influence on stiffness of 
large arteries and central hemodynamics.16–18
The vast majority of patients received massive vasoactive 
therapy (angiotensin-converting-enzyme inhibitor or angio-
tensin II receptor blockers about 60%; β-blockers . 70%; 
calcium channel blockers and nitrates . 20%), both before 
inclusion and throughout the course of our study. One of the 
goals of the study was to find out whether variations in arte-
rial stiffness have an influence on the three-year prognosis of 
patients with CAD, irrespective of change in BP.
As it stands today, only Guerin et al have shown the 
influence of aortic stiffness attenuation on survival of 
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patients (a study of end-stage renal failure patients).19 In 
their study, all patients received antihypertensive therapy at 
inclusion. From entry until the end of follow-up, the changes 
in aortic PWV in response to decreased BP were measured 
using ultrasound. At target BP, patients were separated into 
two groups based on the direction of change in the PWV. 
PWV , like in our study, correlated with ∆SBP (r = 0.54; 
P , 0.0001) and was not tied to variations in biochemical 
parameters or type of applied therapy. Analysis at the end 
of the study revealed that in the group with ∆PWVba $ 0, 
there was a 70% mortality rate, while in the other group, this 
rate was only 26%.
Following the method of Guerin et al19  we  too 
separated patients into groups according to the direction 
of variation in their PWVba in the first six months. For 
85 patients, arterial stiffness either remained unchanged, 
or increased (∆PWVba $ 0), while it decreased for the 
other 76 patients (∆PWVba , 0). Thus, 80% of all MACEs 
occurred in the group with positive PWVba, as compared 
with 20% in the negative PWVba group. Based on our data, 
the sensitivity of PWV was 80% and its specificity was 
54%. For Guerin et al these parameters were 56% and 84%, 
respectively.19
Univariate Cox analysis showed that the absence of 
PWVba decrease in the first six months carried a 3.8 times 
MACE risk increase for these patients. Changes in other 
risk factors were not associated with improved prognosis. 
Adjustment for age and ∆MAP (Model 1), age and smoking 
profile at inclusion, and change in BP and TC at six-month 
follow-up (Model 2), and other factors (Model 3), PWVba 
was found to have maintained its prognostic predictive 
value.
With the exception of statins, there were no differences in 
medication between groups with “positive” and “negative” 
∆PWVba. In the group with “positive” ∆PWVba there was a 
12% higher rate of statin use than in the “negative” ∆PWVba 
group (P = 0.023).
It should be noted that patients who showed a decreased 
PWVba in six months had, on average, higher values of this 
parameter at inclusion in the study than patients with an 
increase in PWVba. In the “negative” ∆PWVba group, at 
inclusion, there were higher values for BP and TC (P , 0.05). 
Taking these facts into account, at baseline, patients showing a 
decrease in arterial stiffness seem to be at higher risk of MACE. 
Also, patients who in the first six months of therapy were found 
to have an increased or unchanged PWVba, likely had more 
advanced vascular lesions which were either irreversible or 
required a more prolonged period of treatment.
Many authors, when discussing pharmacological 
influence on arterial rigidity, separate “acute” effects from 
“chronic” effects. Acute effects are to a greater degree 
connected with reduced vascular tone, while chronic effects 
are mediated through structural modifications of the arte-
rial wall.20,21 In various studies, positive vascular remodel-
ing was evaluated after 6–9 months or more, and was not 
dependent upon other risk factors.16,18,22 These and other 
works have allowed for the 2006 Expert Consensus docu-
ment on arterial stiffness to conclude that arterial stiffness 
attenuation may reflect the true reduction of arterial wall 
damage, whereas BP, glycemia, and lipids can be normal-
ized in a few weeks by using antihypertensive, anti diabetic, 
and lipid-lowering drugs, leading to a strong reduction 
in CV risk scores, but without any improvement yet of   
atherosclerotic lesions and arterial stiffness, which requires 
a long-lasting correction of biochemical abnormalities.12 
Therefore, it can be supposed that a therapeutic strategy, 
having the goal of reducing arterial stiffness, can lead to 
more significant improvement of prognosis than correction 
of individual risk factors.
Conclusion
Decreased PWVba on a six-month background of treatment 
is an independent predictor of favorable prognosis in the 
next three years for men with CAD. Our results suggest that 
for patients with CAD, on a long treatment background, 
reduction of rigidity in large arteries may appear to be a more 
reliable criterion of therapeutic efficacy than the dynamics 
of conventional cardiovascular risk factors.
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